Raed Fanoukh Aboqader Al-Aouadi

Raed Fanoukh Aboqader Al-Aouadi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2025 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
明邵明辰 邵
明辰 邵
MRMohamad Rahmdel
Mohamad Rahmdel
SKSepideh KarkonShayan
Sepideh KarkonShayan
EHElham Hassannia
Elham Hassannia
MKMohammad Khedmatgozar
Mohammad Khedmatgozar
SHSina Hamzehzadeh
Sina Hamzehzadeh

10 March 2026 in Molecules
Verified
Journal Article
Open access
PDF file
Basima A.A. SaleemBasima A.A. Saleem
Basima A.A. Saleem
AQAshraf Ahmed Qurtam
Ashraf Ahmed Qurtam
MEMohamed El-Mokhtar
Mohamed El-Mokhtar
RARaed Fanoukh Aboqader Al-Aouadi
Raed Fanoukh Aboqader Al-Aouadi
AAAli Abdulrazzaq Abdulhussein Alrikabi
Ali Abdulrazzaq Abdulhussein Alrikabi
SFsara mahmoud farhan
sara mahmoud farhan
Multitarget-directed ligands offer a promising strategy for overcoming tumor complexity through simultaneous modulation of complementary oncogenic pathways. In this work, a novel (E)-6-(3-(4-methyl-2-thioxo-2,3-dihydrothiazol-5-yl)-3-oxoprop-1-en-1-yl)-2H-chromen-2-one (compound 6) was synthesized and evaluated as a dual inhibitor of tubulin polymerization and tumor-associated carbonic anhydrases (CAs) IX and XII. Compound 6 displayed potent antiproliferative activity, particularly against MDA-MB-231 triple-negative breast cancer cells (IC50 = 0.37 µM), with excellent selectivity toward non-tumorigenic cells. Mechanistic studies demonstrated strong tubulin polymerization inhibition (IC50 = 3.40 ± 0.09 µM) and submicromolar inhibition of CA IX (IC50 = 0.102 ± 0.005 µM) and CA XII (IC50 = 0.213 ± 0.004 µM), accompanied by downregulation of CA-IX and CA-XII protein expression. Cellular investigations revealed pronounced G2/M phase arrest and apoptosis induction via mitochondrial signaling and caspase activation. Anti-angiogenic activity was supported by inhibition of endothelial migration and concentration-dependent suppression of VEGFR-2 (Tyr1175) phosphorylation in HUVEC cells. Human liver microsomal assays indicated measurable metabolic stability, while molecular docking and in silico ADMET predictions supported target engagement and drug-like properties. Collectively, these findings identify compound 6 as a promising multitarget anticancer lead integrating antimitotic, metabolic, and anti-angiogenic mechanisms.

3 February 2026 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
LWLang Wu
Lang Wu
LDLaylo Djuraeva
Laylo Djuraeva
KFKhaled Fahmi Fawy
Khaled Fahmi Fawy
MKMustafa Jawad Kadham
Mustafa Jawad Kadham
NDNabieva Dildora
Nabieva Dildora
RARaed Fanoukh Aboqader Al-Aouadi
Raed Fanoukh Aboqader Al-Aouadi

24 April 2025 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
HDHaili Duan
Haili Duan
SSSeyedeh Helya Siadat
Seyedeh Helya Siadat
SJSaade Abdalkareem Jasim
Saade Abdalkareem Jasim
PBPooja Bansal
Pooja Bansal
HKHarpreet Kaur
Harpreet Kaur
PKPayam Ali Khiavi
Payam Ali Khiavi

31 March 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
MMMohammed Hashim Mohammed
Mohammed Hashim Mohammed
RARaed Fanoukh Aboqader Al-Aouadi
Raed Fanoukh Aboqader Al-Aouadi
Subasini - UthirapathySubasini - Uthirapathy
Subasini - Uthirapathy
GSGaurav Sanghvi
Gaurav Sanghvi
RMRekha M M
Rekha M M
MUMuhammad Ikram Ullah
Muhammad Ikram Ullah

1 July 2025
Verified
Journal Article
Open access
HAHassan Jabbar Auda
Hassan Jabbar Auda
ABAli Mohammed Barakat
Ali Mohammed Barakat
HSHassan Sarhan Sachet
Hassan Sarhan Sachet
RARaed Fanoukh Aboqader Al-Aouadi
Raed Fanoukh Aboqader Al-Aouadi
ATAdnan Taan Thamer
Adnan Taan Thamer
Coronary artery disease (CAD) remains the leading cause of mortality worldwide, especially in developing countries, with dyslipidemia being a major risk factor. This study aimed to evaluate lipid parameters and inflammatory biomarkers—E-selectin and tumor necrosis factor-alpha (TNF-α)—to understand their roles in the pathogenesis of acute coronary syndrome (ACS). A case-control design was used, involving 120 participants: 60 patients diagnosed with ACS and 60 healthy controls, enrolled between January and December 2024. Blood samples were analyzed to assess lipid profiles, including total cholesterol, triglycerides, HDL, LDL, and VLDL, using a SMART-120 chemistry analyzer. Serum levels of TNF-α and E-selectin were measured using enzyme-linked immunosorbent assay (ELISA). Results showed significant differences in lipid profiles between ACS patients and controls, supporting the impact of dyslipidemia on ACS development. E-selectin levels were significantly elevated in ACS patients (213.26 ± 2.72 pg/mL) compared to controls (175.11 ± 2.71 pg/mL), with P < 0.0001. Similarly, TNF-α levels were higher in patients (83.20 ± 3.88 pg/mL) than controls (45.65 ± 1.79 pg/mL), also with P < 0.0001. ROC curve analysis demonstrated that E-selectin had 96% sensitivity and specificity at a cutoff of 73.44 pg/mL, while TNF-α had 93% sensitivity and 86% specificity at a cutoff of 188.65 pg/mL. Both biomarkers positively correlated with body mass index (r = 0.572, P < 0.0001).The findings suggest that TNF-α and E-selectin are potential diagnostic biomarkers for ACS and play key .